GSK plc (LON:GSK)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1,805.50
-9.00 (-0.50%)
At close: Dec 24, 2025
35.34%
Market Cap72.45B
Revenue (ttm)32.17B
Net Income (ttm)5.49B
Shares Out4.01B
EPS (ttm)1.33
PE Ratio13.59
Forward PE10.07
Dividend0.61 (3.38%)
Ex-Dividend DateNov 13, 2025
Volume1,462,315
Average Volume7,993,358
Open1,803.50
Previous Close1,814.50
Day's Range1,793.00 - 1,806.00
52-Week Range1,242.50 - 1,853.50
Beta0.23
RSI51.45
Earnings DateFeb 4, 2026

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]

Sector Healthcare
Founded 1715
Employees 68,629
Stock Exchange London Stock Exchange
Ticker Symbol GSK
Full Company Profile

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial Statements

News

AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial

On Monday, AstraZeneca Plc (NASDAQ: AZN) released topline data from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi (durvalumab). The trial did not meet the primary endpoint of o...

5 days ago - Benzinga

GSK To Lower Drug Prices

(RTTNews) - GSK plc (GSK, GSK.L) has entered into an agreement with the U.S. Administration to lower the cost of prescription medicines for American patients, including GSK's respiratory portfolio. GS...

5 days ago - Nasdaq

Samsung Biologics To Acquire GSK's Rockville Facility For US$280 Mln

(RTTNews) - Samsung Biologics (207940.KS) announced that its wholly owned U.S. subsidiary, Samsung Biologics America, will acquire 100% of Human Genome Sciences from GSK (GSK, GSK.L) for US$280 millio...

5 days ago - Nasdaq

Samsung Biologics to Acquire Human Genome Sciences from GSK

Samsung Biologics to Acquire Human Genome Sciences from GSK

6 days ago - GuruFocus

Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln

South Korea's Samsung Biologics said on Monday its U.S. unit is buying a U.S. drug production facility from GSK for $280 million.

6 days ago - Reuters

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional investments planned to expand the site's capacity (currently at 60,000 li...

6 days ago - PRNewsWire

Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal

President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. cost...

7 days ago - Benzinga

GSK Reduces Medicine Costs in New U.S. Agreement

GSK Reduces Medicine Costs in New U.S. Agreement

8 days ago - GuruFocus

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.

8 days ago - WSJ

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...

8 days ago - The Guardian

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...

8 days ago - CNBC

GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst

CAMP4 Therapeutics Corporation (NASDAQ: CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE: GSK). The collaboration aims to identify and dev...

8 days ago - Benzinga

GSK (GSK) Resubmits New Drug Application for Antibiotic

GSK (GSK) Resubmits New Drug Application for Antibiotic

8 days ago - GuruFocus

GSK: 2026 Looks Good

9 days ago - Seeking Alpha

A Look Into GSK Inc's Price Over Earnings

In the current market session, GSK Inc. (NYSE: GSK) stock price is at $48.55, after a 0.33% decrease. However, over the past month, the company's stock spiked by 5.29% , and in the past year, by 44.4...

9 days ago - Benzinga

White House Readies Drug Price Deals With AbbVie, Novartis, Roche

AbbVie Inc. (NYSE: ABBV) and several other drugmakers are reportedly expected to announce agreements with the U.S. government on Friday to cut select prescription drug prices and comply with addition...

9 days ago - Benzinga

CAMP4 Therapeutics Teams With GSK On ASO Drug Candidates

(RTTNews) - CAMP4 Therapeutics Corporation (CAMP) on Thursday said it has entered into a strategic research, collaboration and license agreement with GSK to develop antisense oligonucleotide (ASO) dru...

9 days ago - Nasdaq

GSK Gains Approval for New Asthma Treatment, Boosting Stock

GSK Gains Approval for New Asthma Treatment, Boosting Stock

10 days ago - GuruFocus

GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment

GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.

10 days ago - Nasdaq

GSK's Asthma Drug Exdensur Gains FDA Approval, Boosting Growth Prospects

GSK's Asthma Drug Exdensur Gains FDA Approval, Boosting Growth Prospects

10 days ago - GuruFocus

GSK's Asthma Drug Gets U.S. Greenlight--$4 Billion Blockbuster in the Making?

GSK's Asthma Drug Gets U.S. Greenlight--$4 Billion Blockbuster in the Making?

10 days ago - GuruFocus

(EDIT) GSK Gains FDA Approval for Exdensur in Severe Eosinophilic Asthma

(EDIT) GSK Gains FDA Approval for Exdensur in Severe Eosinophilic Asthma

10 days ago - GuruFocus

GSK (GSK) Gains FDA Approval for Exdensur in Asthma Treatment

GSK (GSK) Gains FDA Approval for Exdensur in Asthma Treatment

10 days ago - GuruFocus

GSK wins FDA approval for Exdensur in severe eosinophilic asthma

Understood. Please provide the article for which you would like a meta description.

10 days ago - Seeking Alpha